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Introduction
The Canadian Association of Optometrists (CAO) is the national voice of 
optometry and is dedicated to collaboratively advancing the highest stan-
dard of primary eye care through the promotion of optimal vision and eye 
health, in partnership with all Canadians. 
Optometrists are the front line of eye health and vision care. They are ex-
perts in primary eye care and are well-positioned to help combat the vision-
related complications of diabetes.
CAO assembled the Diabetes Guidelines Working Group to create national 
guidelines on the clinical management of diabetes mellitus in an effort to 
further educate Canadian optometrists and assist them in the management 
of this chronic disease. The Working Group consists of optometrists from 
private practice, research and academia, chosen on the basis of their exper-
tise, experience and representation from across Canada. 
THE DIABETES GUIDELINES WORKING GROUP MEMBERS ARE:
Chris Hudson, BSc (Hons), PhD, MCOptom (UK), PgCUT; 
University of Waterloo, Waterloo, ON
Dianna Leong, BSc, OD; Foresight Eyecare, Calgary, AB
Erin Loewen, BSc, OD; Village Optical, Winnipeg, MB
Derek MacDonald OD, FAAO; Ilex Eye Associates, Waterloo, ON
Angie Machmer, OD; Emerald Park Eye Care, Emerald Park, SK
Ken Mandadakis, BSc, OD; Dr. Ken Mandadakis & Associates, Toronto, ON
Henry Smit, OD; FYidoctors, Truro, NS
Nohad Teliani, BSs, OD; Eye Care Solutions, Edmonton, AB
Benoit Tousignant, OD, MSc, MPH, FAAO; University of Montreal, 
Montreal, QC
EDITING WAS COMPLETED BY:
Chris Hudson, BSc (Hons), PhD, MCOptom (UK), PgCUT; 
University of Waterloo, Waterloo, ON
Derek MacDonald, OD, FAAO; Ilex Eye Associates, Waterloo, ON
Tracy Murphy, MHA, CHE, Consultant, Ottawa, ON
Lois Ross, Editor, Ottawa, ON
DISCLOSURE STATEMENT
The publication of this Guideline was made possible with an unrestricted 
educational grant from Optos Inc . 
DISCL AIMER
These guidelines do not represent a standard of care. Instead, they are 
intended to assist the clinician in the decision-making process. Patient 
care and treatment should always be based on a clinician’s independent 
professional judgment, given the patient’s circumstances, and in compli-
ance with applicable laws and regulations.
The information in this guideline is current to the extent possible at the 
time of publication.
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Abbreviations
A1c Glycated hemoglobin 
AGE Advanced glycation end product
AT	 Artificial	tears
BCVA	 Best	corrected	visual	acuity
CDA CPG	 Canadian	Diabetes	Association	Clinical	 
	 Practice	Guidelines	 
	 (CDA	is	now	Diabetes	Canada)
CE Cataract extraction
CSME	 Clinically	significant	macular	edema	 
	 (or	CSDME:	clinically	significant	 
	 diabetic	macular	edema)
CWS 	 Cotton	wool	spots
DCCT	 Diabetes	Control	and	Complications	Trial	
DED		 Dry	eye	disease
DKA	 Diabetic	ketoacidosis
DM	 Diabetes	mellitus	
DME Diabetic macular edema 
DR Diabetic retinopathy 
DRS Diabetic Retinopathy Study
ECFV	 Extracellular	fluid	volume
ETDRS	 Early	Treatment	Diabetic	 
 Retinopathy Study
FA	 Fluorescein	angiography
FAZ	 Foveal	avascular	zone
FPG	 Fasting	plasma	glucose
GFR	 Glomerular	filtration	rate
HE	 Hard	exudates
HHS	 Hyperosmolar	hyperglycemic	state	
IDRCS International Diabetic Retinopathy  
	 Classification	System
IFG	 Impaired	fasting	glucose	
IGT	 Impaired	glucose	tolerance
IOP	 Intraocular	pressure
IRH	 Intra-retinal	hemorrhages
IRMA	 Intra-retinal	microvascular	abnormalities
MA	 Microaneurysms
ME Macular edema
MRI	 Magnetic	resonance	imaging
NAION	 Non-arteritic	anterior	ischemic	 
 optic neuropathy
NEI	 National	Eye	Institute
NPDR Nonproliferative diabetic retinopathy
NVA	 Neovascularization	of	the	angle
NVD	 Neovascularization	of	the	disc
NVE	 Neovascularization	elsewhere
NVG	 Neovascular	glaucoma
NVI	 Neovascularization	of	the	iris
OCT Optical coherence tomography 
OGTT	 Oral	Glucose	Tolerance	Test
OIS	 Ocular	ischemic	syndrome
PDR Proliferative diabetic retinopathy 
PG	 Plasma	glucose
POAG Primary open angle glaucoma
PRH Preretinal hemorrhage
PRP Panretinal photocoagulation 
PSC	 Posterior	subcapsular	cataract
RD Retinal detachment 
RNFL	 Retinal	nerve	fibre	layer
SLT	 Selective	laser	trabeculoplasty
UKPDS	 United	Kingdom	Prospective	 
	 Diabetes	Study
UWFA	 Ultra-widefield	fluorescein	angiography
VB	 Venous	beading	
VEGF	 Vascular	endothelial	growth	factor
VH	 Vitreous	hemorrhage	
VMT Vitreomacular traction
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Classification, Definitions, Risk Factors
DEFINITION OF DIABETES
Diabetes mellitus is a metabolic disorder characterized by the presence of hyperglycemia due to defective insulin 
secretion, defective insulin action, or both.1 The chronic hyperglycemia of diabetes is associated with microvascular 
complications affecting the eyes, kidneys and nerves, and an increased risk for cardiovascular disease. The criteria 
for diagnosing diabetes are based on thresholds of glycemia that are associated with microvascular disease, particu-
larly retinopathy.
CL ASSIFICATION AND DEFINITIONS
Type 1 diabetes is characterized by the destruction of beta cells in the pancreas. Although the etiology of beta cell 
destruction cannot be established in all cases, it is often the result of an autoimmune process. This usually leads to 
severe insulin deficiency and the patient is prone to develop diabetic ketoacidosis (DKA). DKA is an accumulation 
of ketones in the blood and a decrease in serum pH that occurs when there is insufficient insulin to convert glucose 
to energy and the body breaks down fat cells for energy instead. 
Type 2 diabetes is usually characterized by a combination of insulin resistance and relative insulin deficiency. In-
sulin resistance is often the predominant factor, but deficient insulin secretion can play a more significant role in 
other cases. Between 90 and 95% of all diabetic patients have type 2 diabetes.2 Although type 1 diabetes is associated 
with more frequent and severe ocular complications, because of the much higher incidence of type 2 diabetes, most 
cases of diabetic retinopathy and visual impairment will be type 2.3
Gestational diabetes mellitus refers to glucose intolerance with an onset, or first recognition, during pregnancy.
Prediabetes is a term used to describe impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or a gly-
cated hemoglobin (A1c) level of 6.0 to 6.4%. Any of these findings places an individual at a higher risk of developing 
diabetes. However, individuals with prediabetes do not always progress to diabetes. In fact, a significant proportion 
of people with prediabetes who are diagnosed with IFG or IGT will revert to normal glycemic levels. People with 
prediabetes and concurrent metabolic syndrome (see below) would benefit from cardiovascular risk factor assess-
ment and lifestyle modification.
Metabolic syndrome is diagnosed when a person has at least three of the following risk factors:
• abdominal obesity
• a high triglyceride level
• a low HDL cholesterol level
• high blood pressure
• high fasting blood sugar
The presence of metabolic syndrome increases a person’s risk of developing heart disease, stroke and diabetes.
Hypoglycemia is defined as:4
1. The development of autonomic or neuroglycopenic symptoms
2. A low plasma glucose level (<4.0 mmol/L for patients treated with insulin or an insulin secretagogue)
3. Symptoms that respond to the administration of a carbohydrate
Symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea, tingling, difficulty 
concentrating, irritability, impatience, confusion, weakness, drowsiness, vision changes, difficulty speaking, head-
aches, light-headedness and dizziness. 
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Episodes of hypoglycemia may cause injury if they occur while a patient is driving or engaged in other poten-
tially dangerous activities. Over the long term, some studies have shown that frequent episodes of hypogly-
cemia (five or more since diagnosis) may be associated with a mild decrease in intellectual performance.5,6,7 
Patients with type 2 diabetes who have experienced severe hypoglycemia requiring a visit to the hospital may 
also be at a greater risk of developing dementia in later years.8 After experiencing hypoglycemia, some patients 
may self-adjust their treatment in an attempt to prevent a future episode, potentially leading to worse overall 
glycemic control.9,10,11
Symptoms of hypoglycemia can usually be relieved by the ingestion of 15 grams of glucose (monosaccharide), which 
will produce an increase in blood glucose of approximately 2.1 mmol/L within 20 minutes. Although many patients 
with previous episodes of hypoglycemia carry an ‘emergency’ supply of carbohydrates with them, it would be pru-
dent for optometry offices to have at least one of the following items on hand at all times to support patients who 
experience an in-office episode of hypoglycemia:1
• 15 g glucose in the form of glucose tablets
• 15 mL (3 teaspoons) or 3 packets of table sugar to dissolve in water
• 175 mL (3/4 cup) of juice or regular soft drink
• 6 LifeSavers (1 = 2.5 g carbohydrate)
• 15 mL (1 tablespoon) of honey
Hyperglycemic crisis is a medical emergency that should be suspected and investigated in unwell patients with 
diabetes. It is characterized by DKA and hyperosmolar hyperglycemic state (HHS), and requires immediate treat-
ment and monitoring for metabolic abnormalities and systemic complications. 
Under insulin deficiency, hyperglycemia causes the urinary loss of water and electrolytes (sodium, potassium, chlo-
ride), resulting in depletion of the extracellular fluid volume (ECFV). Whereas DKA occurs as a result of elevated 
glycation levels and absolute insulin deficiency in the case of type 1 diabetes, high catecholamine levels that sup-
press insulin release are implicated in the case of type 2 diabetes.
Symptoms of hyperglycemia include Kussmaul (deep laboured) respiration, acetone-odoured breath (beware mis-
interpretation as alcohol consumption), loss of extracellular fluid volume, nausea, vomiting and abdominal pain. As 
with hypoglycemia, there may also be a decreased level of consciousness.
Patients with DKA or HHS are best managed in a hospital setting. Treatment is directed toward the restoration of 
normal ECFV and tissue perfusion, resolution of ketoacidosis, and correction of electrolyte imbalances and hyper-
glycemia. The existence of concurrent illness should be investigated and treated as required. 
CRITERIA FOR DIAGNOSIS
Canadian Diabetes Association (Diabetes Canada) Clinical Practice Guidelines (CPG) list the diagnostic criteria for 
diabetes as follows:12
• Fasting Plasma Glucose (FPG) ≥7.0 mmol/L (where fasting is defined as no caloric  
 intake for at least 8 hours);
• A1c ≥6.5% (in adults, using a standardized, validated assay in the absence of factors  
 that affect the accuracy of A1c (see below));
• 2-hour Plasma Glucose (PG) in a 75 g Oral Glucose Tolerance Test (OGTT) ≥11.1 mmol/L;
• Random PG ≥11.1 mmol/L (where random is defined as any time of the day,  
 without regard to the interval since the last meal).
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If the individual does not exhibit any symptoms of hyperglycemia and a single laboratory test result falls in the 
diabetes range, a repeat confirmatory test (FPG, A1c, 2-hour PG in a 75 g OGTT) must be performed on another day. 
Ideally, the same test should be repeated for confirmation. A random PG in the diabetes range should be confirmed 
with an alternate, non-random test. If the results of 2 different tests are available and both exceed the diagnostic 
standard, the diagnosis of diabetes is confirmed. 
If the patient already exhibits symptoms of hyperglycemia, the diagnosis can be made on the basis of a single posi-
tive laboratory finding, and treatment can be initiated without delay. When the diagnosis of type 1 diabetes is likely 
(younger or lean individuals with symptomatic hyperglycemia, especially with ketonuria or ketonemia), treatment 
should be initiated on an urgent basis even in the absence of confirmatory testing.
A FPG level of 7.0 mmol/L correlates most closely with a 2-hour PG in a 75 g OGTT value of ≥11.1 mmol/L, and 
each predicts the development of retinopathy. Factors affecting A1c include hemoglobinopathies, iron deficiency, 
hemolytic anemias, and severe hepatic and renal disease. A1c may be misleading in individuals with these and 
other conditions.13 A1c values are also affected by ethnicity and age, and increase by up to 0.1% per decade of 
life.14 A1c is not recommended for diagnostic purposes in children, adolescents, pregnant women, or those with 
suspected type 1 diabetes.
PREVALENCE OF DIABETES MELLITUS
Prevalence is a measurement of all individuals affected by a disease at a particular time, whereas incidence is 
a measurement of the number of new individuals who contract a disease during a particular period of time. 
Table 1 (from the CANSIM Statistics Canada Socioeconomic Database) shows the prevalence of diabetes in 
the Canadian population aged 12 and older (individuals who report that they have been diagnosed by a health 
professional as having type 1 or type 2 diabetes).15 The data appear to indicate that the prevalence of diabetes 
is higher among females in the under-35 age group, but significantly higher in males in later years. However, 
Statistics Canada advises that, due to the relatively low absolute numbers, the data for the under-35 age group 
should be used with caution.
Table 1: Number of Canadians with Diabetes (by Age Group and Gender)
Number of Canadians with Diabetes (by Age Group and Gender)
Males Females Total
12 to 19 Years 5,966 9,910 15,876
20 to 34 Years 29,576 37,057 66,632
35 to 44 Years 73,340 55,453 128,793
45 to 64 years 509,880 323,117 832,997
65 Years and Over 501,670 465,378 967,048
Source: Statistics Canada. (2015). CANSIM, Table 105-0501 and Catalogue no.82-221-X
In July 2011, the Public Health Agency of Canada16 compiled the age-standardized prevalence of persons with 
diabetes by province and territory based on 2008 data from the Canadian Chronic Disease Surveillance System 
(Table 2). While there are relatively small regional differences, diabetes undoubtedly represents a pan-Canadian 
health care issue. 
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Table 2: Age-Standardized Prevalence of Diabetes by Province (%)
Age-Standardized Prevalence of Diabetes by Province (%)
Newfoundland and Labrador 6.5
Prince Edward Island 5.6
Nova Scotia 6.1
New Brunswick 5.9
Quebec 5.1
Ontario 6.0
Manitoba 5.9
Saskatchewan 5.4
Alberta 4.9
British Columbia 5.4
Yukon 5.4
Northwest Territories 5.5
Nunavut 4.4
Source: Public Health Agency of Canada. (2011). http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/ 
facts-figures-faits-chiffres-2011/images/fig_1-2_lg-eng.gif
SCREENING FOR DIABETES
Type 1 diabetes is the result of an immune-mediated destruction of pancreatic beta cells in genetically predisposed 
individuals. Various serological markers may identify at-risk individuals. As there is no intervention at present that 
can delay or prevent the onset of type 1 diabetes, screening is generally not carried out even in persons who have 
been identified as being at risk.
There are a significant number of individuals with undiagnosed type 2 diabetes in the general adult population 
who can be identified by testing for hyperglycemia. Because many of the complications of diabetes are preventable, 
screening of individuals considered to be at risk of type 2 diabetes is beneficial in that treatment can be initiated in a 
timely manner. The CDA CPG recommends that persons over 40 years of age and persons identified as being at risk 
by a valid risk assessment tool be screened for diabetes every three years.17 When additional risk factors are present, 
testing should be initiated earlier and carried out more frequently. Risk factors include:
•	 having a first-degree relative with type 2 diabetes
•	 being a member of a higher-risk ethnic group (Indigenous, African descent, Hispanic, Asian)
•	 having a history of prediabetes or gestational diabetes
•	 having microvascular (retinopathy, nephropathy, neuropathy) complications associated with diabetes
•	 having macrovascular (coronary, peripheral, cerebrovascular) complications associated with diabetes
•	 having metabolic syndrome 
IMPORTANCE OF GLYCEMIC CONTROL
Optimal glycemic control is essential in the management of diabetes and its ocular and systemic complications. A1c 
levels in excess of 7.0% are associated with increased risk of both microvascular and macrovascular complications, 
regardless of the underlying treatment.18 In the Diabetes Control and Complications Trial (DCCT; which studied 
type 1 diabetes), the risk of diabetic retinopathy progression was reduced by 40 to 50% when there was a 10% 
reduction in A1c, although the absolute reduction in risk was significantly less at lower A1c levels.19 In the United 
Kingdom Prospective Diabetes Study (UKPDS; which studied type 2 diabetes), the relationship between A1c levels 
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and diabetes complications was found to be linear: each 1.0% (absolute) reduction in mean A1c was associated with 
a 37% decline in the risk of microvascular complications, a 14% lower rate of myocardial infarction, and a 21% reduc-
tion in deaths from diabetes.20
While relatively stringent glycemic control has been demonstrated to be beneficial, the potential benefits of inten-
sive therapy need to be weighed against the risks of inducing episodes of hypoglycemia. Personalized and higher 
A1c targets may be indicated in older patients with type 2 diabetes who have had diabetes for a long time, have ex-
perienced previous episodes of severe hypoglycemia, and who have coexistent cardiovascular risk factors. The CDA 
CPG provides the following recommended targets for glycemic control (Figure 1):21
Figure 1: CDA CPG-recommended targets for glycemic control
Reprinted from the Canadian Journal of Diabetes, Vol 37, S. Ali Imran, Remi Rabasa-Lhoret, Stuart Ross, Targets for Glycemic Control, Pages S31-S4, 
April 1, 2013, with permission from Elsevier. http://www.sciencedirect.com/science/journal/14992671?sdc=1
MONITORING GLYCEMIC CONTROL
For most individuals, A1c provides a dependable estimate of the mean plasma glucose over the previous three to four 
months: 50% of the result is determined by the mean blood glucose level over the 30 days immediately preceding the 
testing; 40% by levels from 30 to 90 days prior to the test; and the remaining 10% by blood glucose levels from the pre-
vious 90 to 120 days. A1c testing is often carried out quarterly if glycemic targets are not being met and therapy is being 
adjusted. When glycemic targets are consistently being met, A1c testing can be carried out less frequently.
While A1c testing provides very useful average information, it is not an accurate indicator of fluctuating blood 
glucose levels. Self-monitoring of blood glucose can provide additional information about episodes of hypoglyce-
mia and hyperglycemia, and more timely feedback on the short-term effects of diet, lifestyle and pharmacological 
agents. With this additional information, patients can become empowered to make diet and lifestyle choices that 
can reduce the likelihood of large fluctuations in blood sugar levels and subsequent disease complications. 
For persons with type 1 diabetes, daily self-monitoring is essential. Testing three or more times daily has been asso-
ciated with a significant reduction in A1c.22 The evidence supporting self-monitoring is less compelling for persons 
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with type 2 diabetes being treated with insulin. However, for persons with type 2 diabetes who are treated with 
lifestyle management and oral antihyperglycemic medications, self-monitoring coupled with education on how to 
adjust their lifestyle according to the readings can result in a significant reduction of both A1c levels and body mass 
index.23 For people with type 2 diabetes, the benefits of self-monitoring are more significant in the first six months 
after diagnosis.24 In the long term, however, frequent self-checking may not be necessary for patients with type 2 
diabetes who manage their condition with lifestyle changes, with or without oral antihyperglycemic agents.1
EXERCISE AND DIABETES
Physical activity can help individuals with type 2 diabetes achieve better glycemic control, reduce insulin resistance, 
improve lipid profiles, reduce blood pressure, and assist with achieving and maintaining weight loss.25 Aerobic ex-
ercise (activity that involves continuous engagement of large muscle groups for at least 10 minutes) and resistance 
exercise (brief repetitive exercise with weights, weight machines or resistance bands) provide greater benefits for 
diabetes management than exercise directed solely toward improving flexibility. Individuals with diabetes who 
wish to embark on a new regimen of increased physical activity should do so under medical supervision, especially 
when comorbidities are present. 
NUTRITION AND DIABETES
Nutrition counselling and appropriate food choices are integral components of an individual’s self-management of 
diabetes, and can improve glycemic control and prevent or reduce some of the long-term complications of diabetes. 
Nutrition counselling provided by registered dieticians with expertise in diabetes management or trained diabetes 
educators should be individualized, reinforced as needed, and provide the necessary skills for self-management. There 
is no universal prescription for a ‘diabetes diet,’ and effective meal planning should consider factors including the pa-
tient’s age, length of time with the disease, cultural influences and food preferences, financial circumstances and phys-
ical activity level. Components of a healthy diet include carbohydrates (preferably from sources with a low glycemic 
index), dietary fibre, fats (monounsaturated fats are preferred over saturated and hydrogenated fats) and protein from 
a variety of plant or animal sources. CDA’s CPG on Nutrition Therapy1 provides information on dietary considerations.
It is estimated that 80 to 90% of individuals with type 2 diabetes are either overweight or obese. Reducing total 
caloric intake to achieve weight loss of 5 to 10% of initial body weight has demonstrable benefits that include better 
glycemic control, improved insulin sensitivity, reduced blood pressure and improved lipid profiles.26,27,28
Diabetic Retinal Disease
Diabetes mellitus (DM) is a systemic disease with both macro- and micro-vascular complications. The latter often 
involve the retina, and diabetic retinopathy (DR) is the leading cause of preventable vision loss in the working 
population.29,30 The global prevalence of DR in patients with diabetes exceeds 35%, with nearly one in 13 having pro-
liferative disease.31 In light of the fact that one-third to one-half of all people with DM are unaware that they have 
the disease and that early DR is often asymptomatic, regular eye examinations (including dilated retinal assessment, 
particularly for at-risk populations) are of paramount importance for patients diagnosed with or at risk for DM.32
Diabetic retinal disease is multifactorial, and is influenced by both modifiable and non-modifiable risk factors.33,34 
Poor glycemic control is strongly associated with the development of DR, while early and intensive management of 
blood sugar, blood pressure and serum cholesterol has been proven to delay, and in some cases prevent, the onset 
and progression of DR.19,35,36 However, given enough time, most patients with DM will develop some degree of reti-
nopathy.37 Some ethnicities (Indigenous, African descent, Hispanic and Asian) are more likely to develop diabetes 
and DR.38 Physical activity is beneficial, while smoking and obesity are significant risk factors.39,40,41,42,43 All these pro-
cesses can be exacerbated by the onset of puberty or pregnancy.44,45 Also, the initiation of intensive insulin treatment 
may result in an initial worsening of DR six to 12 months later, which then improves over time. The risk of early 
worsening is acceptable in light of the long-term benefits of intensive treatment.46
Through several pathways, chronic hyperglycemia leads to leukostasis, basement membrane thickening, loss of retinal 
capillary pericytes and endothelial cells, and a loss of smooth muscle in retinal arterioles, resulting in capillary bed insta-
bility, decompensation, and eventual collapse.47,48,49,50 Ischemia and advanced glycation end products (AGEs) up-regulate 
vascular endothelial growth factor (VEGF), which is thought to be the primary cytokine that mediates increased vascular 
permeability and new blood vessel growth.51,52 While VEGF is essential for cell survival, the over-expression of VEGF can 
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be catastrophic: increased vascular permeability resulting in diabetic macular edema and new blood vessel growth in 
both posterior and anterior segments of the eye are major causes of vision loss in patients with DM. 
While microvascular complications have received the most attention, a growing body of evidence suggests that pri-
mary neuronal (glial cell) impairment, chronic vascular and neuronal inflammation, and insulin resistance within 
the retina itself play important roles, particularly in early (preclinical) DR.53 Ideally, further investigation will en-
able the earlier diagnosis of DR through both functional (electrophysiological and psychophysical) and structural 
assessments, and identify alternate and perhaps more effective treatment strategies.
These and other events have been proposed to drive the progression of diabetic retinal disease through a series of 
well-defined stages of increasing severity defined by the landmark Early Treatment Diabetic Retinopathy Study 
(ETDRS), each of which carries an elevated risk of loss of vision.54 Diabetic macular edema (DME), the most com-
mon cause of vision loss in persons with diabetes, may present at any point in the DR continuum.55
THE DIABETIC RETINOPATHY CONTINUUM
The International Diabetic Retinopathy Classification System (IDRCS), which is based on the ETDRS, defines the 
progression of DR.54 The ETDRS followed the Diabetic Retinopathy Study (DRS), commissioned by the National 
Eye Institute (NEI) to evaluate the efficacy of laser photocoagulation, which had become widely used in the man-
agement of advanced nonproliferative and proliferative DR despite a lack of good-quality supporting evidence.56 
The DRS treated one eye in each of nearly 1,800 patients, with the fellow eye as an untreated control, and concluded 
that argon laser photocoagulation reduced the risk of severe vision loss by at least 50%, particularly in the pres-
ence of high-risk neovascularization involving the optic nerve head and/or accompanied by vitreous hemorrhage.57 
Questions about the timing of laser treatment and its effect on macular edema (ME) prompted the follow-up ET-
DRS, a multicentre study involving nearly 4,000 patients with bilateral retinopathy in which one eye was random-
ized to early photocoagulation and the other to deferred photocoagulation.58 The results indicated that early and 
relatively aggressive photocoagulation reduced the risk of severe vision loss by nearly 25% and the development of 
high-risk proliferative DR by approximately 50%.59
Based on these landmark trials, the natural history of untreated but carefully monitored DR was studied, and the 
following continuum of DR development was articulated.
a) No apparent retinopathy
Diabetes-related microvascular dysfunction can begin very shortly after the onset of DM.60 Early and clinically un-
detectable changes (preclinical DR, often beginning with subtle venous dilation) initiate the progression through 
the DR continuum.61
b) Nonproliferative diabetic retinopathy (NPDR)
i. Mild NPDR 
Mild NPDR encompasses the earliest clinically detectable diabetes-related retinal abnormalities. 
a. Microaneurysms (MA) 
Mild NPDR is characterized by increased vascular permeability due to the development of retinal MA, 
which reflect the focal weakening of capillary walls possibly resulting from a loss of pericyte support.62 
During retinal examination, MA appear as sharp isolated red dots of varying size. Only MA at least 30 
microns in diameter are visible on ophthalmoscopy.63 Leakage of MA may lead to local retinal edema, 
hard exudates and/or intra-retinal hemorrhages (IRH). IRH are distinguished from MA primarily on 
the basis of diameter; they are larger than 125 microns.64 If MA leakage involves the fovea, mild NPDR 
can still result in significant vision loss. 
ii. Moderate NPDR 
Moderate NPDR includes the characteristics of mild NPDR and one or more of the following: 
a. Intra-retinal hemorrhages (IRH) 
As noted above, leakage of MA, or retinal capillaries or venules, may lead to IRH. Their appearance 
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depends upon their location in the retina. IRH within the outer plexiform or inner nuclear layers have 
a dot (smaller and relatively well-defined) or blot (larger and ill-defined) appearance, respectively, 
whereas hemorrhages within the retinal nerve fibre layer (RNFL) appear flame- or splinter-shaped as a 
result of the anatomic contours of the nerve fibre layer.65 Spontaneous occlusion of MA or accumulation 
of platelet/fibrin material may result in a white-centred retinal hemorrhage, or Roth spot. Although 
they are not specific to DR, when found in a patient known to have diabetes, Roth spots are not likely 
to be the sequelae of other serious systemic conditions (leukemia, bacterial endocarditis, or anemia, 
among others).66 IRH secondary to DM are usually restricted to the posterior pole, resolve within 
several months, and have no impact upon vision unless they are physically at the fovea. Isolated atypical 
hemorrhaging (for example, extensive RNFL hemorrhaging or mid-to-far peripheral IRH) should raise 
suspicion of alternate etiologies (retinal vein occlusion or ocular ischemic syndrome, respectively).67,68 
However, mid-peripheral retinal ischemia is strongly associated with DME and proliferative 
retinopathy. Mid-to-far peripheral IRH in a patient with longstanding diabetes warrants further 
investigation, likely including wide-field fluorescein angiography.69,70
b. Hard exudates 
Hard exudates (HE) represent the intra-retinal accumulation of serum lipoproteins that have leaked 
from excessively permeable capillaries, and herald the presence of past or current retinal edema.71 
Appearing as well-defined glistening yellow/white crystals, HE can be isolated or assume a circinate or 
star-shaped pattern around a leaking capillary or MA. HE may be resorbed spontaneously or following 
laser surgery that reduces retinal edema. Like IRH, they typically remain asymptomatic unless there is 
foveal photoreceptor involvement or, in the case of longstanding HE, disciform scar formation.72
c. Cotton wool spots (CWS) 
Cotton wool spots, also referred to as soft exudates, are focal fluffy gray/white lesions that result 
from axoplasmic stasis and expulsion of axoplasmic material into the surrounding retinal tissue 
within the RNFL.73 These lesions arise following pronounced retinal ischemia from several etiologies. 
In patients with DM, they are often accompanied by extensive dark-blot IRH secondary to partial 
arteriolar occlusion or complete occlusion followed by reperfusion, and usually signify more advanced 
NPDR.74,75 CWS are typically asymptomatic and resolve within several months, but if persistent may 
cause permanent localized RNFL atrophy.76,77 Clinicians should note that a transient increase in CWS 
is possible in early DR following the initiation or augmentation of systemic treatment that achieves 
better glycemic control.78 For this reason, CWS alone are not reliable indicators of ischemic-driven 
progression of DR. However, if accompanied by other ischemic indicators, the presence of CWS 
corroborates concern regarding a substantial loss of retinal perfusion.
iii. Severe NPDR 
As the course of DR progresses, arteriolar rather than capillary closure is thought to cause more severe 
ischemia, resulting in CWS, an increase in IRH (particularly dark-blot hemorrhages), and venous beading 
(VB).79 The diagnosis of severe NPDR is based upon the extent and severity of the following abnormalities: 
a. Intra-retinal hemorrhages 
As described previously, but particularly including dark-blot hemorrhages.
b. Venous beading (VB) 
Venous beading represents a focal irregularity in the venous calibre secondary to degeneration of 
the vessel wall within or adjacent to areas of extensive capillary closure.80 These and other less 
common retinal vascular changes, including venous loops and reduplications, are strong predictors of 
progression to proliferative diabetic retinopathy (PDR).81
c. Intra-retinal microvascular abnormalities 
Intra-retinal microvascular abnormalities (IRMA) are dilated telangiectatic capillaries connecting diseased 
arterioles and venules within or adjacent to areas of extensive capillary non-perfusion.82 Like VB, IRMA are 
considered to be precursors of PDR and can be difficult to differentiate from neovascularization. PDR results 
in the growth of new vessels forward to incarcerate the vitreous while IRMA are limited to within the same 
retinal tissue. IRMA tend to leak less than new vessels during fluorescein angiography.83
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Severe NPDR is diagnosed by satisfying any single criterion of the “4:2:1 Rule” with no evidence of 
proliferative (neovascular) disease:84
• IRH in all 4 of the retinal quadrants
• definite VB in 2 or more retinal quadrants
• prominent IRMA in 1 or more retinal quadrant(s) 
iv. Very severe NPDR 
Very severe NPDR is diagnosed by satisfying any two or more criteria of the “4:2:1 Rule” with no evidence 
of proliferative (neovascular) disease.
In the ETDRS,84 one eye of each patient was assigned to early photocoagulation and the other to deferral of treat-
ment so that the natural history of DR could be observed (treatment was initiated in the deferred eyes once patients 
became at high risk for the development of neovascularization). Data analysis showed that dark-blot hemorrhages, 
VB and IRMA were indicators of retinal ischemia, and all were significantly associated with the progression of DR to 
proliferative disease. For this reason, the advent of dark-blot hemorrhages, VB and IRMA should be interpreted with 
caution due to the much higher propensity for sight loss. From an optometric perspective, dark-blot hemorrhages, VB 
and IRMA usually justify referral to a retinal specialist for evaluation, including fundus fluorescein angiography to de-
termine the presence and severity of capillary non-perfusion. CWS are also thought to reflect ischemic changes, but do 
not predict progression partly because they can transiently increase following intensive PG control. Unless associated 
with the other retinal lesions indicative of increased ischemia, careful monitoring of patients with CWS is appropriate. 
c) Proliferative diabetic retinopathy (PDR)
Proliferative diabetic retinopathy is characterized by the growth of new and structurally fragile blood vessels (neovas-
cularization) into the subhyaloid space, and eventually into the vitreous itself. These vessels are often accompanied 
by a developing framework of fibrous/glial tissue and arise most often at the boundary of perfused and non-perfused 
retinal tissue:85 New vessels on or within one disc diameter of the optic nerve head (disc) are referred to as neovascu-
larization of the disc (NVD), while new vessels beyond this boundary are called neovascularization elsewhere (NVE). 
While both NVD and NVE are ominous signs, the former carries a more guarded prognosis for future vision loss.
The sight-threatening sequelae of PDR are subhyaloid/vitreous hemorrhage and tractional retinal detachment.86 
These new vessels incarcerate the vitreous and are prone to hemorrhage with any amount of vitreous traction.87 
This hemorrhage can empty into the subhyaloid or preretinal space as a preretinal hemorrhage (PRH) or into the 
vitreous cavity as a vitreous hemorrhage (VH). Vitreous contraction can result in tractional retinal detachment 
(RD), especially in the presence of accompanying fibrous/glial tissue proliferation.88,89
Although the ETDRS differentiated between early and high-risk PDR (the latter shows more extensive NVD or any 
NVD/NVE accompanied by PRH/VH), progression to severe vision loss is unfortunately common with any degree 
of proliferative disease, and necessitates the consideration of panretinal photocoagulation and/or anti-VEGF injec-
tion should it be detected.90,91
The identification of retinopathy as early as possible affords the best opportunity for timely and effective interven-
tion, and the maintenance or restoration of optimal vision and vision-related quality of life. 
d) Diabetic macular edema (DME)
Diabetic macular edema is defined as retinal thickening within one disc diameter (~1500 microns) of the centre of 
the macula.92 DME is the most common cause of vision loss in patients with diabetes and may present at any point 
in the DR continuum from no apparent DR to NPDR to PDR.93 DME arises from a loss of integrity of the blood-
retina barrier, and may be focal or diffuse. The former is due to localized leakage of individual MA within the retinal 
circulation and is often accompanied by HE, while the latter involves widespread leakage of the damaged capillary 
bed and/or choroidal plexus.94
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The International Clinical Diabetic Macular Edema Disease Severity Scale classifies DME as absent or present 
based on the results of a stereoscopic retinal exam. If present, the examiner must determine whether it meets the 
criteria for clinical significance, implying that it represents an imminent threat to vision by encroaching upon the 
fovea.58,95 
i. DME absent 
DME is classified as absent if there is no apparent retinal thickening or HE detected through stereoscopic 
examination of the posterior pole.
ii. DME present 
DME is classified as present if there is retinal thickening or HE detected through stereoscopic examination 
of the posterior pole.96
• minimal DME: edema or HE distant from the fovea
• moderate DME: edema or HE encroaching upon but not involving the fovea
• severe DME: edema or HE involving the fovea
For clinicians who are primarily concerned about the risk of vision loss secondary to DME, the ETDRS defined 
clinically significant (diabetic) macular edema based upon the proximity of the edema with respect to the centre of 
the macula.
iii. Clinically significant (diabetic) macular edema (CSME or CSDME)95,97 
Clinically significant (diabetic) macular edema represents an imminent threat to vision because it 
encroaches upon or involves the fovea, and was specifically defined by the ETDRS as:
• retinal thickening at or within 500 microns (approximately one-third of a vertical disc diameter)  
 of the centre of the macula; and/or
• HE at or within 500 microns (approximately one-third of a vertical disc-diameter) of the centre  
 of the macula with adjacent retinal thickening; and/or
• retinal thickening of one disc-diameter in size, at least part of which is within one disc-diameter  
 of the centre of the macula.
Subsequent to the ETDRS, objective imaging technologies such as optical coherence tomography (OCT) have rein-
forced the notion that the risk of vision loss from DME, as well as the need for treatment, is greatest when the fovea 
is involved.
iv. Central-involved (diabetic) macular edema 
The advent of OCT has allowed the detection of subtle amounts of retinal edema and the recognition  
of central-involved diabetic macular edema, defined as ME affecting the central 1mm retinal subfield.98
e) Ischemic maculopathy
Ischemic maculopathy is characterized by the presence of foveal avascular zone (FAZ) abnormalities. Ischemic macu-
lopathy is the consequence of extensive capillary closure and non-perfusion in the posterior pole and may result in sig-
nificant and irreversible loss of central vision as a result of capillary ‘drop-out.’99 Fundus fluorescein angiography (FA) 
is required to definitively diagnose ischemic maculopathy.100 “Optical coherence tomography angiography (OCTA) 
may become an alternative to FA for this purpose.”101 On clinical examination, CWS associated with dark-blot hem-
orrhages within the macula are also indicative of ischemic maculopathy. From an optometric perspective, ischemic 
maculopathy may present as an otherwise unexplained loss of vision in a patient with diabetes. 
Given the devastating impact of diabetes, early detection (through annual comprehensive eye examinations) and 
timely treatment of DR is critical to avoiding permanent impairment.102,103
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The presence of DR is also predictive of other micro- and macrovascular complications (including mortality, car-
diovascular disease, cerebrovascular disease, peripheral neuropathy and nephropathy), further emphasizing the 
important role and responsibility of the primary care optometrist in the care of the patient.104,105,106,107,108,109
SUMMARY OF STAGING OF DIABETIC RETINOPATHY
See the table in Appendix 1, which incorporates the diagnostic characteristics, recommended follow-up, and refer-
ral criteria for different stages of DR. 
Non-Retinal Ocular Complications of Diabetes Mellitus
Family physicians and endocrinologists often look to optometrists for information about the status of their patient’s 
diabetes. While they are most often concerned about DR, diabetes mellitus can have many other effects on the eye 
and visual system. 
REFRACTIVE CHANGES
It is not uncommon for a patient with diabetes to present with complaints that their vision has changed dramati-
cally in a short period of time. Sometimes these changes can be found in established diabetic patients, but this may 
be the first symptom of diabetes that a patient experiences. The timeframe for return of refraction to the pre-hy-
perglycemic state depends on how quickly the patient’s blood sugar returns to a more appropriate level; the patient 
must be counselled that stabilization may take weeks or months. 
OCUL AR-SURFACE DISEASE
Patients with diabetes have a higher prevalence of ocular-surface disease including Meibomian gland dysfunction, 
elevated tear-film osmolarity and tear-film instability, and corneal anesthesia.110,111,112,113,114 Diabetes-related neuropa-
thy and proliferative disease can also be risk factors for tear-film and ocular-surface disorders in DM.115 The most 
common symptom that patients present is dry eye, both aqueous-deficient and evaporative. These patients have an 
up to a 33% higher prevalence of dry eye, and women are approximately 50% more susceptible than men.116 Reduced 
corneal sensitivity associated with diabetes leaves the cornea vulnerable to asymptomatic trauma and may cause a 
delay in wound healing, resulting in persistent epithelial defects and corneal ulcers.117 Impaired re-epithelialization 
of corneal defects has been well-documented, primarily due to weak and abnormal adhesions between the epithe-
lium and the basement membrane directly beneath it.118 The accumulation of AGEs on the basement membrane is 
a contributing factor. As a result, the cornea in the diabetic patient is not always an effective barrier to infection: as 
the patient’s A1c increases, the ability of the cornea to act as a barrier decreases.119 An abrasion that typically heals 
in a day in most patients may take 2 to 3 days to heal in a patient with diabetes, and treatment must therefore be 
tailored with this in mind.
CATARACT 
While everyone can expect to develop a cataract if they live long enough, cataracts are more common and seen 
much earlier in patients with diabetes. One theory regarding the mechanism behind this greater frequency is that 
higher glucose levels in the blood lead to the oxidation of crystalline lens proteins.120 Specifically, aldose reductase 
catalyzes the reduction of glucose to sorbitol and initiates the oxidative pathway. As the levels of sorbitol accumu-
late in the crystalline lens, osmotic stress leads to apoptosis (programmed cell death), which in turn leads to cata-
ract formation.121 Cataracts are classified by the layer or location of the opacity: in order of decreasing frequency, 
diabetes tends to cause posterior subcapsular (PSC) cataracts, followed by cortical cataracts, then nuclear sclerotic 
cataracts. Snowflake cataracts, while rare, are essentially pathognomonic of diabetes. 
PRIMARY OPEN ANGLE GL AUCOMA
Glaucoma is a group of diseases that damage the retinal ganglion cells that form the optic nerve and can result in 
permanent vision loss, including blindness, if left untreated. Glaucoma is usually asymptomatic until a considerable 
amount of permanent damage has occurred. There are many types of glaucoma, and primary open angle glaucoma 
(POAG) is the most common in the North American population. The role of diabetes in the development of glau-
coma has been controversial, and several studies have reached contradictory conclusions.122,123 Recently however, 
several systematic reviews and meta-analyses have demonstrated that individuals with diabetes have on average 
a two- to three-fold increased risk of developing POAG, likely a result of the chronic micro-vascular compromise 
that characterizes diabetes and contributes to glaucomatous optic neuropathy.124,125 Certain populations of patients 
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with diabetes have a higher risk of developing glaucoma, including those with poor glycemic control and those of 
Hispanic ethnicity.126,127 
RUBEOSIS IRIDIS (NEOVASCUL ARIZATION OF THE IRIS; NVI) 
Neovascularization of the iris is the result of ischemia secondary to chronic retinal vessel disease, and may be found 
in most patients with proliferative retinopathy. Profound hypoxia results in the formation of new blood vessels on 
the surface of the iris and in the anterior chamber angle of the eye. These weak and leaky vessels can hemorrhage, 
become fibrotic and shut down the angle, leading to increased intraocular pressure (IOP) and often painful neovas-
cular glaucoma. 
NEOVASCUL AR GL AUCOMA (NVG) 
As noted above, neovascular glaucoma is a devastating complication of the release of VEGF that accompanies the 
chronic retinal ischemia characterizing PDR. Physical obstruction of the trabecular meshwork often leads to sig-
nificant elevations in IOP that require incisional surgery (trabeculectomy or a glaucoma drainage device), cyclode-
structive procedures, or goniotomy.128 Regardless of the intervention, unfortunately, the prognosis is guarded.
DIABETIC PAPILLOPATHY AND ANTERIOR ISCHEMIC OPTIC NEUROPATHY 
Diabetic papillopathy is edema of the optic nerve in a diabetic patient caused by leakage of the vascular bundles and 
swelling of the retinal ganglion cell axons in and around the optic nerve.129 It is rare, often self-limiting, presents 
with little impact on visual acuity, and can be unilateral or bilateral. Individuals with either type 1 or 2 diabetes are 
at an increased risk for developing this condition, which can occur even in the metabolically controlled population, 
often when they are quite young. While vision is initially unaffected, diabetic papillopathy may be associated with 
rapid progression of retinopathy, including NVD.
Although this position is controversial, some investigators have argued that diabetic papillopathy and non-arteritic 
anterior ischemic optic neuropathy (NAION) exist on a continuum, with the former representing a relatively minor 
manifestation of the latter, which may result in optic atrophy and permanent impairment of vision. The incidence 
of NAION is significantly higher in the presence of diabetes,130,131 and as many as one in four patients with NAION 
have concurrent diabetes mellitus.132 
OCUL AR ISCHEMIC SYNDROME
Ocular ischemic syndrome (OIS) is a relatively rare condition that arises due to the ocular hypo-perfusion that ac-
companies carotid artery occlusive disease.133 Symptoms include, but are not limited to, ocular pain and transient or 
permanent visual loss. Approximately half of patients initially present with visual acuities ranging between 20/20 
and 20/50 in the affected eye, but nearly 1/3 have count fingers or worse vision.134 Pain that results from ischemia 
can develop over the course of a few days, is typically dull, and can be alleviated by lying down. In contrast, pain 
from IOP can come on quickly. The pain accompanying OIS can radiate to the periorbital and temple regions, and 
care must be taken to differentiate it from giant cell arteritis. Retinal signs of the chronic hypoperfusion that accom-
panies OIS can include dilated vessels, mid-peripheral dot and blot hemorrhages and proliferation of neovascular 
membranes.135 Anterior segment findings may include uveitis and neovascularization of the iris.135
The ocular manifestations of OIS can be difficult to differentiate from DR, especially when the two conditions are 
concurrent, and over 50% of patients with OIS have diabetes.136 Unilateral or marked asymmetry of DR or NVI war-
rants further evaluation for carotid occlusive disease.136
CRANIAL NERVE PALSIES RESULTING IN OCUL AR MOVEMENT DISORDERS 
The three cranial nerves (oculomotor [CN3], trochlear [CN4] and abducens [CN6]) that control the six extraocular 
muscles can be affected by diabetic microvascular compromise. The oculomotor and abducens nerves are involved 
most frequently, followed by the trochlear nerve.137
The oculomotor nerve innervates three rectus (superior, inferior, and medial) and the inferior oblique muscles, the 
levator palpebrae superioris, and iris sphincter. Its paresis results in diagonal diplopia due to deviation of the eye 
down and out. This may be accompanied by ptosis and pupil dilation with anisocoria greater in the light. However, 
the pupil is often spared in diabetes-associated CN3 compromise, whereas mydriasis and pain are often found in 
paresis secondary to aneurysmal compression.
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The abducens nerve controls the lateral rectus. When paretic, the patient will also experience diplopia, but it will be 
horizontal due to esotropia that is greater at a distance than at near. Sudden-onset CN6 palsy must be differentiated 
from giant cell arteritis, myasthenia gravis, medial wall fracture, intracranial hypertension and thyroid (restrictive) 
orbitopathy.
When the trochlear nerve is affected, the patient will experience diagonal diplopia, in this case due to involvement 
of the superior oblique muscle. CN4 palsy also results in small torsional rotation of the eye. Patients with this con-
dition often learn to adopt a head-tilt to compensate. Differential diagnoses include multiple sclerosis, aneurysms, 
intracranial hypertension, head trauma and tumours.
Diagnosis of Ocular Complications of Diabetes Mellitus
In the provision of primary eye care, the optometrist plays a crucial role in detecting ocular manifestations of sys-
temic disease, including diabetes. Particularly when the patient and optometrist have a long history together, chang-
es in both ocular structure and ocular function can be observed over time. The following recommendations for the 
optometric examination of diabetic patients should facilitate the detection of potentially sight-threatening diabetic 
eye disease.
OPTOMETRIC EXAMINATION OF A PATIENT WITH DIABETES
When examining a patient with diabetes, optometrists should consider the following elements of the patient’s med-
ical history:138
1. Type and duration of diabetes: type 1, type 2, or gestational (self and family) 
2. Current diabetes treatment (diet, oral medications, insulin type and dosage) 
3. Blood sugar and glycemic control (including most recent fasting (spot) and A1c values) 
4. Level of compliance with blood glucose control 
5. History of diabetic retinopathy: date of diagnosis, level of severity, and treatments 
6. Blood pressure and cholesterol/lipid status and treatment 
7. Presence of co-existing kidney disease: note glomerular filtration rate (GFR) 
8. Presence of peripheral or autonomic neuropathy
Optometrists should be active participants within a multidisciplinary health care team including, but not limited to, 
the primary care physician, diabetes educator, nutritionist, endocrinologist and nephrologist.
ENTRANCE TESTING
Habitual and best-corrected (or pinhole) visual acuities should be assessed, with special attention paid to any re-
duction in best-corrected acuity and refractive shifts that may be attributable to fluctuations in blood glucose. Pupil 
assessment may reveal sluggish responses, and ocular motility may be impacted by cranial nerve palsies involving 
CN3, CN4 and CN6. Confrontation visual field testing may reveal peripheral constriction, particularly if there is a 
history of panretinal photocoagulation.
ANTERIOR SEGMENT EXAMINATION
Slit lamp biomicroscopic examination of the anterior eye may reveal signs of dry eye syndrome or corneal defects 
indicative of poor wound healing. Careful examination of the iris is necessary to rule out neovascularization of the 
iris (NVI) and gonioscopy may be required if there is suspicion of new vessel growth involving the angle, raising the 
risk of neovascular glaucoma (NVG). Regular tonometry will reveal any changes in intraocular pressure. Examina-
tion of the crystalline lens is important, as patients with diabetes frequently develop posterior subcapsular, cortical, 
nuclear, and, more rarely, snowflake cataracts. Snowflake cataracts consist of gray-white opacities reminiscent of 
snowflakes.139 
DIL ATED FUNDUS EXAMINATION 
Stereoscopic slit lamp funduscopy through a dilated pupil is essential for the detection of diabetic retinopathy, 
including DME, which is the most common cause of vision loss in diabetes (see Section 3: Diabetic Retinal Dis-
ease). The use of mydriatic agents is generally safe unless contraindicated by a high risk of angle closure. The high 
magnification afforded by direct ophthalmoscopy may be helpful in the detection of NVD, but its clinical utility is 
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otherwise limited by the lack of stereopsis. Binocular indirect ophthalmoscopy is indicated, particularly when there 
is poor blood sugar control in patients with long-term diabetes due to concerns of peripheral ischemia.
RETINAL IMAGING
Digital fundus photography is key for documenting and monitoring diabetic retinal findings.140,141 Ultra-widefield 
photography may be used as an ancillary imaging technique.142,143 More recently, OCT has become important for 
detecting and quantifying retinal thickening, which is key in the diagnosis and assessment of DME. It is important 
to note that neither photography nor objective imaging should be viewed as a substitute for dilated fundus exami-
nation, but rather should serve as useful ancillary documentation, monitoring and educational tools. In remote and 
underserved communities with limited access to optometric or ophthalmologic services, telemedicine protocols 
may be established to aid in diagnosing DR. 144
Intravenous fundus fluorescein angiography may be necessary to determine the extent of retinal ischemia, par-
ticularly in the presence of advanced nonproliferative retinopathy, any level of proliferative retinopathy, and DME. 
Ultra-widefield fluorescein angiography (UWFA) can also be a useful tool for detecting peripheral retinal isch-
aemia.70,145
SUMMARY OF EXAMINATION PROCEDURES 146,147 
Procedure Potential diabetes-related ocular complications
Case history Pertinent details and risk factors as noted above
Visual acuity: aided, pinhole Decreased/shifted from normal/previous; fluctuating vision
Pupil reflexes Sluggish light and near responses 
Ocular alignment: cover test
Cranial nerve 3, 4, or 6 palsies
Extra-ocular motility testing
Visual field testing
Loss of sensitivity
Peripheral scotomas from panretinal photocoagulation
Tear film and ocular surface Dry eye syndrome
Cornea Reduced corneal sensitivity and wound healing ability
Iris Neovascularization of the iris (NVI)
Lens
Early onset of nuclear, cortical and posterior subcapsular cataracts; more 
rarely, snowflake cataracts
Gonioscopy Neovascularization of the angle (NVA)
Tonometry Increased IOP (neovascular glaucoma and POAG)
Vitreous Vitreous hemorrhage; vitreoretinal fibrosis
Retina 
• dilated fundus exam is required
• digital fundus photography is 
 recommended
• OCT is recommended when clinical exam 
  suggests DME or an unexplained change  
 in visual acuity
DR and/or DME/CSDME
SUGGESTED TIMELINES
Patients with type 1 diabetes should have annual screenings for DR beginning 5 years after the onset of their disease. 
Patients with type 2 diabetes should be examined promptly at the time of diagnosis, and an annual recall schedule 
will help ensure they are not lost to follow-up.148 
Women who develop gestational diabetes do not require an eye examination during pregnancy and do not appear 
to be at increased risk of developing DR during pregnancy. However, patients with diabetes who become pregnant 
should be examined early in the course of their pregnancy.148
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At each exam, it is important to review glycemic control, blood pressure and lipid control, assess the patient for 
other non-ocular diabetes complications, provide counselling to the patient, and provide a report to the family phy-
sician and endocrinologist, if applicable.
If retinopathy is present, the stage of severity of retinopathy will establish appropriate monitoring intervals or trig-
ger a referral for treatment (see Section 3: Diabetic Retinal Disease). 
See the table in Appendix 1, which incorporates the diagnostic characteristics, recommended follow-up, and refer-
ral for different stages of DR. 
DIABETIC MACUL AR EDEMA AND CLINICALLY SIGNIFICANT MACUL AR EDEMA
Diabetic macular edema (DME) can occur at any stage of DR. Clinical assessment includes the stereoscopic exami-
nation of the macular area through a dilated pupil using a hand-held lens and slit lamp (stereo fundus biomicrosco-
py) to detect retinal thickening with or without accompanying hard exudates.149 OCT can assess macular thickness 
both qualitatively and quantitatively, and may assist in differentiating DME from other maculopathies (ischemic 
maculopathy, taut posterior hyaloid membrane, subfoveal serous detachment, etc.).150,151,152,153
As discussed in Section 3, clinically significant diabetic macular edema (CSME) is a strictly defined form of DME 
involving retinal thickening that encroaches on the fovea. The detection of CSME should trigger a referral to an 
ophthalmologist for consideration of treatment. A review should occur at least every six months following treat-
ment once the patient is stable.
Optometrists should counsel patients on the importance of complying with follow-up eye care to aid in the early de-
tection, and ideally prevention, of visual loss, and emphasize that micro-vascular changes like those detected within 
the eyes can also occur in other areas of the body. Patients with DR must recognize that they may have normal vi-
sion and visual acuity even in the presence of advanced levels of nonproliferative or proliferative retinopathy and/
or ME. Providing brochures and website references may enhance compliance. An optometric report to the family 
physician and/or endocrinologist is essential for timely collaborative follow-up care of the patient with diabetes. 
Management of Ocular Complications of Diabetes Mellitus
Treatment of the ocular complications of DM is largely dictated by the severity of the ocular disease, although 
consideration must be given to the age and wishes of the patient, the desired visual outcome, and systemic and 
ocular comorbidities. Important aspects of treatment include vigilant monitoring, education about improved blood 
glucose control and systemic health, and prompt referral to an ophthalmologist when medical or surgical treatment 
is indicated.
Ocular complications may be the presenting signs of diabetes, arising prior to the diagnosis of the disease itself. 
In such situations, the patient must be referred for systemic diagnostic testing while treatment of the diabetic eye 
disease begins. The following review of the management of diabetic eye disease will assume that the patient has ei-
ther been previously diagnosed with diabetes or that the appropriate systemic diagnostic testing has been initiated.
MANAGEMENT OF RETINAL COMPLICATIONS
Monitoring and education:
In the case of mild to moderate NPDR without DME, examination by an optometrist should occur every 6 to 12 
months, with careful scrutiny for progression. If the NPDR advances to a severe level or if DME is detected, the 
patient should be referred to an ophthalmologist. 
Patient education regarding the effects of diabetes on ocular and systemic health and emphasizing the benefits of 
improved blood glucose control is imperative. Collaboration with the family physician and/or endocrinologist is es-
sential to facilitate improved control of the diabetes and comorbidities.148 A certified diabetes educator may also be 
an important part of the health care team.
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Medical and surgical treatment:
1) Laser photocoagulation
a) Focal/grid photocoagulation 
Focal/grid photocoagulation is used in the management of DME. Despite the risks, which include choroidal 
neovascularization, subretinal fibrosis, and iatrogenic visual field loss, focal photocoagulation remains an 
acceptable and effective treatment for DME, particularly if there is no centre/foveal involvement.154,155
b) Panretinal photocoagulation (PRP) 
PRP is still used in eyes with proliferative retinopathy, particularly those that are considered to be at high 
risk based on the ETDRS (see Section 3: Diabetic Retinal Disease). While there are risks involved with PRP 
itself (most notably iatrogenic peripheral visual field loss and an increased risk of DME), PRP has been 
shown to reduce the risk of severe vision loss (Best corrected visual acuity (BCVA) of ≤5/200) by 50% in 
patients with high-risk PDR, defined as the presence of any three of the following:88,91
• Neovascularization of the disc (NVD)
• Neovascularization elsewhere (NVE)
• Severity of neovascularization 
• NVD > ¼ disc area in size 
• NVE > ½ disc area in size
• Preretinal or vitreous hemorrhage
2) Vitrectomy
a) Vitreous hemorrhage (VH) 
In the case of a central vitreous hemorrhage, particularly if it is non-clearing or recurring, timely 
vitrectomy is recommended; delayed vitrectomy is associated with less satisfactory outcomes.156  
b) Vitrectomy for DME 
The vitreous is believed to contribute to DME through abnormally glycosylated and cross-linked vitreous 
collagen causing vitreomacular traction (VMT).157 For this reason, vitrectomy (and consequent release of 
the VMT) may be considered in eyes with concurrent DME and VMT, and at least moderate vision loss.156,157 
Further, in patients with diabetes, the vitreous is known to contain exceedingly high levels of VEGF, 
essentially bathing the retina in VEGF and creating an optimal environment for breakdown of tight junctions 
at the inner and possibly the outer retinal barrier.158 Research suggests that performing vitrectomy earlier 
gives more predictable results and less risk of complication than vitrectomy on eyes with PDR.156,159 The 
primary risks associated with vitrectomy for DME are post-operative VH and retinal detachment.157 
Of note, one study found no increased risk of peri- or post-operative hemorrhage following vitrectomy in pa-
tients on systemic anti-coagulant therapy. Patients undergoing vitrectomy should not have to discontinue use of 
anti-coagulants.160 
3) Intraocular steroids
 Intraocular steroids (most commonly triamcinolone, fluocinolone acetonide and dexamethasone) are 
another treatment option for DME. These steroids can be delivered through intravitreal injection, or 
implanted in a sustained-release format. While intravitreal injections of steroids can successfully reduce 
DME, their effect is short-lived, meaning that sustained-release implants may be a superior mode of 
delivery.161 Sustained-release implants are injected through the pars plana as an outpatient procedure. The 
effects of the treatment last approximately 6 months.162
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 Complications can arise related to intravitreal steroids: increases in IOP and the development or progression of 
cataracts must be monitored closely. With sustained-release implants, the rates of these particular complications 
are particularly high: increased IOP is reported in 3 to 64% of patients (with lower rates when low-dose steroid 
implants are used) and cataracts requiring extraction within four years are found in 75 to 91% of patients.161,163 
Another serious complication is VH; less significantly, pruritis and an unusual sensation in the eye may be 
reported. Because of the complication rate, intraocular steroids may be best reserved for patients with recurrent 
or persistent DME. It has also been suggested that a focal or grid laser is preferred over triamcinolone injection 
since, while these treatments provide similar outcomes regarding visual acuity, the adverse effects are less 
significant with laser treatment.164 Steroid treatment may also be used in conjunction with other treatment 
modalities (such as grid or focal laser, or PRP), rather than as a stand-alone treatment.165
4) Vascular endothelial growth factor inhibitors (anti-VEGFs)
 VEGF is thought to be up-regulated by hypoxia and increased plasma glucose, and is found in higher 
concentrations in the retina and vitreous in patients with DR. VEGF increases the permeability of blood 
vessels and drives neovascularization. Anti-VEGFs decrease vessel permeability and reverse angiogenesis, 
and have become widely and successfully used in the treatment of DME and PDR.166
 The anti-VEGFs most commonly used include:
• ranibizumab (Lucentis) – approved by Health Canada for treatment of DME
• bevacizumab (Avastin) – not approved by Health Canada, but often used off-label  
 for the treatment of DME
• aflibercept (Eylea) – approved by Health Canada for treatment of DME
 Intraocular injections of anti-VEGFs are now considered to be first-line treatment in eyes with DME. 
The initial treatment is typically every 4 to 6 weeks, then less frequently for a period of time determined 
by the treating ophthalmologist, typically guided by OCT-assessed retinal thickness and morphology.167 
Anti-VEGFs have also shown promise in the treatment of PDR. A recent randomized trial demonstrated 
that patients treated with ranibizumab had better central acuity and peripheral visual field sensitivity, and 
lower incidences of VH and DME than patients treated with PRP alone.168
 Combined therapies for DME are gaining popularity. Pharmacotherapy has been shown to complement 
focal/grid laser photocoagulation in the management of DME,169 and may reduce the treatment burden 
in these patients.170 Additional large-scale, prospective, multi-centre, randomized, controlled trials for 
evaluating the role of combination therapy in DME are needed.171
MANAGEMENT OF NON-RETINAL OCUL AR COMPLICATIONS
Refractive changes
Transient changes in refractive error associated with fluctuating blood glucose levels are commonly seen in patients 
with diabetes, and appropriate patient counselling is advised. A change in refractive correction may be required, as 
indicated by the patient’s BCVA and visual requirements. However, it is recommended to defer prescribing refrac-
tive correction for patients with recently diagnosed diabetes or who are undergoing intensive glycemic control until 
normalization of blood glucose and stabilization of refractive error.172,173 For the established diabetic, re-education 
on proper glucose control is important, while for the patient who has not been diagnosed with diabetes, a referral 
to their family physician for further investigation is indicated. In either case, once proper glycemic control is estab-
lished, the refraction typically returns to its original state.174
Ocular-surface disease
Ocular-surface disease is more common in patients with diabetes, particularly in the presence of poor blood sugar 
control. Therefore, careful screening for dry eye disease (DED) in all patients with diabetes is recommended. Research 
shows that DED is associated with the duration of diabetes, A1c, and the presence of retinopathy; therefore, it may be 
beneficial to counsel patients on the benefits of glycemic control for the prevention of DED as well as retinopathy. 175,176
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Early diagnosis and treatment of DED is important for preventing secondary infection, corneal ulceration and scar-
ring, and reduced quality of life. DED management in patients with and without diabetes is identical: the mainstays of 
management include artificial tears (AT), hot compresses and lid hygiene, topical anti-inflammatory agents (including 
corticosteroids and cyclosporine A), environmental modification, oral tetracycline derivatives, and punctal/lacrimal 
occlusion.116,177 Oral omega-3 fatty acids have been shown to improve DED symptoms in patients with diabetes.178
Treatment of neurotrophic keratitis is aimed at achieving epithelial healing and preventing further corneal damage. 
Management involves treatment of underlying ocular-surface disease, often involving the use of preservative-free 
AT. Moderate presentations may require topical autologous serum AT, antibiotics, bandage contact lenses and/or 
collagen shields. Referral to an ophthalmologist may be required for more advanced neurotrophic keratitis; man-
agement options include the use of amniotic membrane, tarsorrhaphy, and conjunctival flap.179
Given the potential impact of diabetes on the ocular surface, some optometrists may have concerns about contact 
lens use. A review of the literature indicates that patients with diabetes can wear contact lenses as safely as patients 
without diabetes, provided there are no contraindications such as significant ocular-surface disease.180
Cataract
Careful assessment of refractive error and optimization of refractive correction is recommended for patients with 
cataract. If visual acuity cannot be improved sufficiently by refractive correction or if visualization of the retina is 
obscured by cataract, referral to an ophthalmologist for cataract extraction (CE) is recommended. 
While visual improvement is achieved with CE in most patients with NPDR, improvement may be limited in pa-
tients with DME, PDR and/or poor pre-CE BCVA.181,182 Careful pre-operative patient education regarding realistic 
surgical outcomes is advised.183 Pre-operative treatment of severe NPDR or DME by photocoagulation or anti-VEG-
Fs may result in better post-CE outcomes.181,184,185
Evidence regarding the progression of DR and development of macular edema following CE is mixed.181,182,186,187,188
While cataract surgery may be required once the patient’s visual function starts to affect the activities of daily living, 
other treatment options to delay the need for surgical intervention have been investigated. Studies have shown that 
certain antioxidants (such as Vitamin B6 and N-acetylcysteine) can slow the oxidation that leads to early cataract 
formation. Another study found that high doses of Vitamin E combined with insulin helped reduce cataract forma-
tion in diabetic rats.189 Delaying CE in the patient with DR provides some time to stabilize the condition. If the reti-
nopathy is not controlled or is unstable, the risk of post-operative complications, especially ME, rises exponentially. 
CE before the presentation of proliferative disease is also of merit.190
Primary open angle glaucoma
While most POAG cases in patients with diabetes can be controlled with topical pharmaceutical agents, some pa-
tients require surgical intervention. Selective laser trabeculoplasty (SLT) has been found to be a safe and effective 
primary and adjunctive treatment for open-angle glaucoma.191 However, there is contradictory evidence on its ef-
ficacy in the diabetic population.192 
Rubeosis iridis and neovascular glaucoma
Neovascular glaucoma (NVG) is a complication of PDR that results from neovascularization of the iris (NVI) and 
anterior chamber angle. Early detection of NVI is critical, and necessitates immediate treatment with PRP, often ac-
companied by anti-VEGF injections to reduce the neovascular drive.193 In addition to PRP and anti-VEGFs, manage-
ment of NVG often involves medical and surgical treatment (typically the latter) to lower a markedly elevated IOP 
that results from secondary angle closure.194 The visual prognosis is unfortunately quite poor.195
Diabetic papillopathy and anterior ischemic optic neuropathy 
In patients with suspected diabetic papillopathy, other causes of disc edema must be ruled out to confirm the di-
agnosis.196 While there is no generally accepted treatment for diabetic papillopathy and most cases resolve without 
sequelae over a few months, anti-VEGF injections or periocular steroids have been used for treatment.197,198,199,200
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Patients with diabetes are at higher risk for developing non-arteritic anterior ischemic optic neuropathy 
(NAION),132,201 one of the more common causes of acute optic nerve injury in individuals 50 years of age or older. 
There is currently no generally accepted treatment for NAION.202
Ocular ischemic syndrome (OIS)
Patients suspected of having OIS should be evaluated with carotid Doppler ultrasound to assess carotid patency, 
intravenous fluorescein or indocyanine green angiography to identify retinal ischemia and neovascularization, as 
well as a detailed anterior segment evaluation given the risk of NVI and NVG. Detection of underlying carotid occlu-
sive disease is essential. While OIS arises from carotid stenosis, emboli from the carotid arteries can lead to retinal 
artery occlusion and ischemic optic neuropathy.135 The prognosis for patients diagnosed with OIS is generally poor, 
and prompt patient referral for assessment by specialists in ophthalmology, internal medicine, cardiology and/or 
neurology is recommended.203
Cranial nerve palsies resulting in ocular movement disorders
As a result of the microvascular ischemia that accompanies diabetes, hypertension and hyperlipidemia, palsies of 
the third, fourth or sixth cranial nerves are relatively common. Consequently, patients with diabetes have a higher 
incidence of cranial nerve palsies than the general population.204,205,206
In the setting of cranial nerve palsy, it is important to rule out non-microvascular etiologies, which may require 
neuro-imaging such as magnetic resonance imaging (MRI).205 If the underlying vascular disorder is addressed, the 
prognosis for cranial nerve palsy with confirmed microvascular etiology is good, with gradual resolution over 8 to 12 
weeks.207 Options for the management of diplopia prior to its spontaneous resolution include monocular occlusion 
or Fresnel prism.
MANAGEMENT OF COMORBIDITIES AND SYSTEMIC COMPLICATIONS OF DIABETES MELLITUS
Several issues need to be managed in patients diagnosed with DM, including glycemic control, blood pressure con-
trol, cholesterol levels, cardiovascular risks and weight management. While these matters are typically the purview 
of the family physician and/or endocrinologist, optometrists and other members of the patient’s health care team 
may also play a role. 
Concluding Remarks
People with diabetes are at risk for several ophthalmic complications, including diabetic retinopathy, many of which 
remain asymptomatic until quite advanced. Consequently, regular, ideally annual, comprehensive eye examinations 
are important for everyone with diabetes, as prompt diagnosis and timely treatment afford the best opportunity to 
prevent or minimize vision loss.
Optometrists who are familiar with the risk factors, diagnostic classification, follow-up schedules and referral cri-
teria for these complications are well-positioned to provide accessible, quality eye care. As active participants on a 
multidisciplinary health care team, optometrists also play an integral role in patient education, by emphasizing the 
importance of optimal diabetes control and overall health management to reduce the risk of ophthalmic and other 
complications of the disease.
These guidelines are intended to assist optometrists with the complex decisions that characterize the care of pa-
tients with diabetes. They are informed by seminal and contemporary high-quality evidence and are the product of 
a guideline-development process that reflects good practice. Due to the ongoing evolution of our understanding of 
diabetes and DR, these guidelines should be considered a work in progress. Feedback is welcome and can be sent to 
the Canadian Association of Optometrists at info@opto.ca
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Appendix 1: Diagnostic characteristics, recommended follow-up, and referral by stage  
of diabetic retinopathy
Suggested Frequency of Eye Examination for Patients with Diabetes 
(subject to resource availability, specifically medical/surgical retinal specialists)
Stage of 
retinopathy
Diagnostic 
characteristics
Macular 
status
Frequency of 
Examination
Referral Timing and Treatment
No apparent 
retinopathy
No abnormalities No DME Every 12 months No referral necessary
Mild NPDR MA
No DME Every 12 months No referral necessary
DME Every 4 to 6 months No referral necessary
CSME Every month Within 1 month: consider focal laser, anti-VEGF
Moderate NPDR
MA
IRH
HE
CWS
No DME Every 6 to 12 months No referral necessary
DME Every 3 to 6 months
No referral necessary: monitor carefully for 
CSME
CSME Every month Within 1 month: consider focal laser, anti-VEGF
Severe or very 
severe NPDR
Any one of  
‘4:2:1 Rule’:
4: IRH (particularly 
dark-blot IRH) in  
4 retinal quadrants
2: venous beading 
in 2+ quadrants
1: IRMA in 1+ 
quadrant
Very severe NPDR: 
2 or more features 
of severe NPDR
No DME Every 2 to 6 months 
If very severe, within 1 month: consider PRP
Review at least every 6 months once stabilized
DME Every 2 to 4 months
If very severe, within 1 month: consider PRP
Review at least every 6 months once stabilized
CSME Every month
Within 1-2 weeks: consider PRP, focal laser, 
anti-VEGF
Review at least every 6 months once stabilized.
PDR
NVD
NVE
VH
PRH
No DME Every 2 to 4 months
Within 2 weeks: consider PRP
Review at least every 6 months once stabilized
DME Every 2 to 3 months
Within 2 weeks: consider PRP
Review at least every 6 months once stabilized.
CSME Every month
Within 1 week: consider PRP, focal laser, anti-
VEGF
Review at least every 6 months once stabilized
High-risk PDR
Severe NVD:  
larger than 1/4  
to 1/3 disc area
Severe NVE:  
larger than  
1/2 disc area
VH or PRH with 
fibrovascular 
proliferation or 
tractional RD
No DME
Every 2 to 3 months 
 
Within 1 week: PRP and/or anti-VEGF
Review at least every 6 months once stabilized
DME Every 1 to 3 months
Within 1 week: PRP and anti-VEGF; consider 
focal laser
Review at least every 6 months once stabilized
CSME Every month
Within 1 week: PRP and anti-VEGF; consider 
focal laser
Review at least every 6 months once stabilized
Diabetic macular edema (DME) is defined as: Retinal thickening or HE detected through stereoscopic examination of the 
posterior pole, but not within the criteria set for clinically significant macular edema (CSME).
CSME is defined as: Retinal thickening at or within 500 microns of the centre of the macula; and/or HE at or within 500 
microns of the centre of the macula with adjacent retinal thickening; and/orRetinal thickening of one disc-diameter in size, at 
least part of which is within one disc-diameter of the centre of the macula.
Refer CSME to ophthalmology for immediate treatment (within 1-2 weeks if accompanied by more advanced retinopathy). 
Review at least every 3 to 6 months once stabilized. 
A patient with sudden severe vision loss or signs/symptoms of retinal detachment should be immediately referred to an 
ophthalmologist able to treat proliferative disease/CSME.
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Other abbreviations: CWS, cotton wool spots; DR, diabetic retinopathy; HE, hard exudates; IRH, intraretinal 
hemorrhages; IRMA, intraretinal microvascular anomalies; MA, microaneurysms; NPDR, nonproliferative diabetic 
retinopathy; NVD, neovascularization of the disc; NVE, neovascularization elsewhere; PDR, proliferative diabetic 
retinopathy; PRH, preretinal hemorrhage; PRP, panretinal photocoagulation; RD, retinal detachment; VEGF, vascu-
lar endothelial growth factor; VH, vitreous hemorrhage
The above table was informed by:
American Academy of Ophthalmology Retina/Vitreous Panel. 2016. Diabetic Retinopathy Preferred Practice Pat-
tern. Available at: www.aao.org/ppp.
American Optometric Association. American Optometric Association Evidence-Based Clinical Practice Guideline: 
Eye Care of the Patient with Diabetes Mellitus. St. Louis, MO: American Optometric Association; 2014. Available at: 
https://www.aoa.org/Documents/EBO/EyeCareOfThePatientWithDiabetesMellitus%20CPG3.pdf 
Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee. COS ev-
idence-based clinical practice guidelines for management of diabetic retinopathy. Can J Ophthalmol. 2012;47:1-30. 
International Council of Ophthalmology. ICO Guidelines for Diabetic Eye Care. San Francisco, CA: International Council 
of Ophthalmology; 2017. Available at: http://www.icoph.org/downloads/ICOGuidelinesforDiabeticEyeCare.pdf  l
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Clinically significant macular edema 
This 56-year old Guyanese man has intra-retinal hemorrhages/microaneurysms and retinal thickening just 
inferior to (within 500μm of) the fovea. Macular OCT shows speckled intra-retinal fluid and a small cyst at 
the level of the inner plexiform layer. The outer retina is unremarkable, and best acuity remains 6/6. 
Early nonproliferative diabetic retinopathy and clinically significant macular 
edema 
This 56-year old Indian man has prominent hard exudate (HE) accumulation and intra-retinal 
hemorrhaging with associated retinal thickening throughout the macula, and several inferior cotton wool 
spots. Macular OCT shows very hyper-reflective HE predominantly involving the inner and outer nuclear 
layers (note the deeper shadowing posterior to the hyper-reflective HE). A less hyper-reflective 
microaneurysm (margin more reflective than center) is present just nasal to the fovea. Speckled central 
intra-retinal fluid and outer retinal thickening are also present nasally (note the ‘saw tooth’ appearance of 
the outer plexiform layer). The ellipsoid zone is slightly irregular, although best acuity remains 6/6-. 
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Early nonproliferative diabetic retinopathy and clinically significant macular 
edema, post-anti-VEGF treatment 
30 months post-anti-VEGF treatment, this now 58-year old Indian man shows a significant decrease in HE, 
and fewer intra-retinal hemorrhages and cotton wool spots. Macular OCT shows less hyper-reflectivity and 
secondary shadowing, but persistent (in fact, slightly increased) speckled IRF in the inner and outer 
nuclear layers. The ellipsoid zone remains irregular, more superior-nasal than central, with best acuity of 
6/7.5. 
Moderate nonproliferative diabetic retinopathy and clinically significant macular 
edema 
This 75-year old Caucasian man shows multiple intra-retinal hemorrhages and cotton wool spots, hard 
exudates in a circinate pattern superior to the fovea, and a retinal nerve fiber layer hemorrhage along the 
inferior arcade. Macular OCT shows speckled IRF and hyper-reflective hemorrhages/microaneurysms 
predominantly temporal to the fovea. Despite the macular edema, the ellipsoid zone remains intact with 
best acuity of 6/6. Referral for anti-VEGF therapy was recommended, but declined. 
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Moderate nonproliferative diabetic retinopathy and clinically significant macular 
edema (18 months post-initial presentation) 
Eighteen months after initial presentation, this now 76-year old Caucasian man shows less intra-retinal 
hemorrhaging, HE, and cotton wool spot formation, and resolution of the retinal nerve fiber layer 
hemorrhage along the inferior arcade. Clinical macular exam suggested persistent thickening, particularly 
temporally. This was confirmed by OCT, which showed a significant increase in speckled IRF temporal to 
the fovea, and diffuse outer retinal thickening and hyper-reflective foci (the latter thought to represent 
activated inflammatory/microglial cells) nasal to the fovea. The ellipsoid zone remains intact with best 
acuity of 6/6. Referral for anti-VEGF consultation was again recommended, but again declined. 
Moderate nonproliferative diabetic retinopathy and clinically significant macular 
edema (20 months post-initial presentation) 
Within several months, this 76-year old Caucasian man returned with increasing blur, and best acuity had 
dropped to 6/18. Not surprisingly, macular OCT showed increased diffuse outer retinal thickening, more 
hyper-reflective foci, and much larger cystic cavities in the inner nuclear layer. At this point, referral was 
accepted: anti-VEGF treatment was initiated, and follow-up is ongoing. 
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Neovascularization of the disc 
This 46-year old Caucasian woman with a history of gestational diabetes in her early 20s presented 15 
years ago with signs suggesting diabetic retinopathy, and was subsequently diagnosed with type 2 
diabetes mellitus. Blood sugar control was mediocre, and the patient developed bilateral diabetic macular 
edema and macular ischemia in the right eye. An additional oral hypoglycemic agent and weight loss led 
to a decrease in retinopathy; however, peripheral neuropathy and a poorly healing leg ulcer prompted the 
addition of insulin. The patient subsequently presented with moderate NPDR, CSME, and bilateral 
neovascularization of the disc. Despite this, best acuity remained 6/7.5 in both right and left eyes. Referral 
for consideration of anti-VEGF and/or pan-retinal photocoagulation was initiated, with follow-up pending. 
Proliferative diabetic retinopathy 
This 45-year old Caucasian woman with a 35-year history of type 1 diabetes underwent pan-retinal 
photocoagulation (PRP) in her early 40s following the development of NVD, which subsequently showed 
some regression. The retina exhibited scattered dot and blot hemorrhaging and ghost vessels, 
predominantly in the temporal macula, and peripheral laser scarring. Two years later, she developed a 
vitreous hemorrhage (VH) secondary to traction on several persistent neovascular fronds; her acuity 
remained good (6/6-) and her retinal specialist recommended observation as the hemorrhage cleared. 
Within several months, proliferative vitreoretinopathy with tractional retinal elevation and a smaller VH 
along the superior arcade was noted (see photo). Repeat retinal consult yielded the recommendation to 
continue observation: aside from a third small central VH that quickly resolved, the clinical picture and 
visual acuity have remained stable for the subsequent two years. 
